• Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
300
On Slideshare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
4
Comments
0
Likes
1

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. 3 Key Points from Abbott Labs’s Q2 Earnings You Need to Know
  • 2. A Bounce Back Quarter for Abbott • Abbott’s earnings jumped 17.4% en route to topping analyst estimates in Q2 • Sales climbed 1.9% YOY, also beating projections • Abbott’s diagnostics division posted the quarter’s best result, with revenue climbing nearly 5% Source: Abbott Labs Media
  • 3. Point #1: Emerging Markets Take Center Stage • Emerging markets have become Abbott’s brightest hope for strong future growth • The strong dollar continues to hurt, negatively impacting revenue by 1.1 percentage points • Abbott’s generics business posted strong results from emerging markets despite unit’s overall flat sales • Key Emerging Markets, including BRIC nations and 10 other markets, recorded 9.7% generic drug revenue growth in Q2
  • 4. The Generics Business’s International Flair • Abbott’s generics business is poised to become an emerging market leader • Company acquired Russian drugmaker Veropharm and Chilean generics company CFR Pharmaceuticals in Q2, boosting long-term presence in Latin America and Russia • A huge opportunity at stake: The Latin American pharmaceutical market is projected to grow by 116% between 2008 and 2021, according to CitigroupSource: Wikimedia Commons
  • 5. Mylan Makes the Difference • Abbott’s sale of its Developed and Other Markets generics unit to Mylan boosts growth hopes • Developed market generics revenue declined by 4.4% YOY in Q2, weighing down overall growth • Abbott’s $5.3 billion sale of the unit to Mylan will allow the company to concentrate on expanding generic footprint in emerging markets • Company already is the largest drugmaker in fast-growing India • Keeping its Indian leadership is paramount: McKinsey projects 14.5% annual growth in India’s drug market between 2009 and 2020
  • 6. Point #2: Are Nutritionals Back on Track? • Nutritionals sales made up more than 31% of Abbott’s overall revenue in Q2 • Unit bounced back from a weak Q1 with 1.6% revenue growth • Adult nutritional sales, while not the biggest opportunity, posted a strong 4.4% revenue uptick Source: Wikimedia Commons
  • 7. What’s Ahead for Nutrition? • Abbott must keep up in Chinese infant nutrition market • August 2013’s supplier recall cost Abbott $40 million in Q2 – down from $75 million in Q1 - as overall international pediatric nutrition revenue declined by 2.2% • Abbott’s investments in China in Q2, including a new nutrition factory, will help – but company needs to close the gap with rivals, particularly China market leader Mead Johnson. • Mead Johnson owns roughly 16% of Chinese market share according to Morningstar analyst estimates, ahead of Abbott’s share of between 10% and 14% • Too much opportunity to ignore: Zenith International projects China to account for 2/3 of global infant nutrition market growth between now and 2018
  • 8. Point #3: Medical Devices Still Under Pressure • Medical device revenue returned to growth in Q2, but U.S. market still under fire • U.S. device sales slid by 5.4% YOY, continuing an overall 6.1% sales drop through 2014’s first half • Pricing pressure and stiff competition are likely to continue to weigh on Abbott’s business
  • 9. Finding Heart in Device Sales • The cardiac device market has struggled lately, but Vascular Device sales mounted a turnaround overseas • Vascular device sales account for 55% of Abbott’s overall device revenue • U.S. sales are still under pressure, but international revenue makes up nearly two- thirds of Vascular Device revenue. • If Abbott can continue to push growth overseas, the device business will be poised for better days ahead • Still no luck for stents: Drug-eluting and bioresorbable stent sales fell nearly 5% in quarter. • Keep an eye on Abbott’s Absorb stent: If the Absorb receives FDA approval in the future, Abbott will have a major innovative product edge on rivals
  • 10. Looking Ahead • Abbott slightly boosted its full-year earnings outlook, with guidance of between $2.19 and $2.26 in per-share earnings in line with Wall Street’s expectations • However, if Abbott can return to growth in international pediatric nutrition sales while retaining strong diagnostics revenue growth, this company could surprise
  • 11. The simple investing strategy that can transform your financial future Dividend-paying stocks like Abbott Labs simply crush their non-dividend-paying counterparts. Don’t our analyst report on a group of high-yielding stocks that should be in any income investor’s portfolio.